A bioengineered in situ ovary (ISO) supports follicle engraftment and live-births post-chemotherapy.

Autor: Buckenmeyer MJ; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA.; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA., Sukhwani M; Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Iftikhar A; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA.; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Nolfi AL; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA.; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Xian Z; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA., Dadi S; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA., Case ZW; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Steimer SR; Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., D'Amore A; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Fondazione RiMED, Palermo, Italy., Orwig KE; Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Brown BN; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA.; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Jazyk: angličtina
Zdroj: Journal of tissue engineering [J Tissue Eng] 2023 Nov 17; Vol. 14, pp. 20417314231197282. Date of Electronic Publication: 2023 Nov 17 (Print Publication: 2023).
DOI: 10.1177/20417314231197282
Abstrakt: Female cancer patients who have undergone chemotherapy have an elevated risk of developing ovarian dysfunction and failure. Experimental approaches to treat iatrogenic infertility are evolving rapidly; however, challenges and risks remain that hinder clinical translation. Biomaterials have improved in vitro follicle maturation and in vivo transplantation in mice, but there has only been marginal success for early-stage human follicles. Here, we developed methods to obtain an ovarian-specific extracellular matrix hydrogel to facilitate follicle delivery and establish an in situ ovary (ISO), which offers a permissive environment to enhance follicle survival. We demonstrate sustainable follicle engraftment, natural pregnancy, and the birth of healthy pups after intraovarian microinjection of isolated exogenous follicles into chemotherapy-treated (CTx) mice. Our results confirm that hydrogel-based follicle microinjection could offer a minimally invasive delivery platform to enhance follicle integration for patients post-chemotherapy.
Competing Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
(© The Author(s) 2023.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje